Printer Friendly

PHC Holdings Closes USD 1.14bn Acquisition of Thermo Fisher Scientific's Anatomical Pathology Business.

M2 EQUITYBITES-July 2, 2019-PHC Holdings Closes USD 1.14bn Acquisition of Thermo Fisher Scientific's Anatomical Pathology Business

(C)2019 M2 COMMUNICATIONS http://www.m2.com

2 July 2019 - Tokyo, Japan-based healthcare company PHC Holdings Corp. (PHCHD) has closed the acquisition of the anatomical pathology business of Massachusetts, US-based biotechnology product development company Thermo Fisher Scientific Inc. (NYSE: TMO) for approximately USD 1.14bn, the company said.

Aiming to achieve further business growth, PHCHD will expand its business portfolio through the acquisition of the business from Thermo Fisher.

PHC Holdings Corp. is a global healthcare company that offers value-added products and services across diabetes care, diagnostics, life sciences and healthcare IT. Its subsidiaries include PHC Corp. and Ascensia Diabetes Care Holdings AG.

Thermo Fisher Scientific Inc. (NYSE: TMO) is in serving science, with revenues of more than USD 20bn and approximately 70,000 employees globally.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jul 2, 2019
Words:155
Previous Article:Readen Holding Closes Acquisition of Two Percent Group, Including All Associated Brands and Licenses.
Next Article:Harsco Closes USD 625m Acquisition of Clean Earth from Compass Group.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters